Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes. Issue 12 (19th August 2014)

• Record Type: Journal Article
• Authors: Tremblay, A. J.; Lamarche, B.; Kelly, I.; Charest, A.; Lépine, M.‐C.; Droit, A.; Couture, P.
• Is Part Of: Diabetes, obesity & metabolism. Volume 16:Issue 12(2014:Dec.)
• Page Start: 1223
• Page End: 1229
• Publication Date: 2014-08-19
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12359
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12359-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="dom12359-sec-0001" sec-type="section"> <title>Aim</title> <p id="dom12359-para-0001">To investigate the effects of sitagliptin therapy on the kinetics of triglyceride‐rich lipoprotein (TRL) apolipoprotein (apo)B‐48, VLDL apoB‐100, apoE and apoC‐III in patients with type 2 diabetes.</p> </sec> <sec id="dom12359-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12359-para-0002">Twenty‐two subjects with type 2 diabetes were recruited in this double‐blind crossover study, during which the subjects received sitagliptin (100 mg/day) or placebo for a 6‐week period each. At the end of each phase of treatment, the <italic>in vivo</italic> kinetics of the different apolipoproteins were assessed using a primed‐constant infusion of <sc>l</sc>‐[5, 5, 5‐D3]leucine for 12 h, with the participants in a constantly fed state.</p> </sec> <sec id="dom12359-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12359-para-0003">Sitagliptin therapy significantly reduced fasting plasma triglyceride (−15.4%, p = 0.03), apoB‐48 (−16.3%, p = 0.03) and free fatty acid concentrations (−9.5%, p = 0.04), as well as plasma HbA1c (placebo: 7.0% ± 0.8 vs. sitagliptin: 6.6% ± 0.7, p < 0.0001) and plasma glucose levels (−13.5%, p = 0.001), without any significant effect on insulin levels. Kinetic results showed that treatment with sitagliptin significantly reduced the pool size of TRL apoB‐48 by −20.8% (p = 0.03), paralleled by a reduction in the production rate of these particles (−16.0%, p = 0.03). The VLDL apoB‐100 pool size was also significantly decreased by sitagliptin therapy (−9.3%, p = 0.03), mainly because of a reduction in the hepatic secretion of these lipoproteins, although this difference did not reach statistical significance (−9.2%, p = 0.06).</p> </sec> <sec id="dom12359-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="dom12359-para-0004">Treatment with sitagliptin for 6 weeks reduced triglyceride‐rich apoB‐containing lipoprotein levels by reducing the synthesis of these particles.</p> </sec> </abstract>